The new direct oral anticoagulants (DOACS) dabigatran, rivaroxaban, apixaban and
edoxaban provide alternatives to warfarin for treatment and prevention of atrial fibrillation …

The direct oral anticoagulants (DOACs), now including dabigatran, apixaban and
rivaroxaban, have given clinicians alternative options to low molecular weight heparins …

Anticoagulant therapy monitoring provides the largest volume of work in most routine
coagulation laboratories. 1–3 Currently, the main anticoagulant armamentarium comprises …

Most studies on the sensitivities of coagulation assays to direct oral anticoagulants (DOACs)
are based on normal plasma spiked with anticoagulant in the laboratory. Recent studies …

Objectives: To study dabigatran etexilate, a new oral anticoagulant that functions as a direct
thrombin inhibitor. Methods: This study evaluates four methods, one of which is performed in …

Background: Assessing the anticoagulant effect of dabigatran may be useful in certain
clinical settings. When plasma sampling is not available, serum or urine samples may …

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may
be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of …

Guidance regarding dabigatran monitoring has been published [1, 2], but the specific assays
are not all targeted to low levels of dabigatran encountered in the preoperative setting. For …

Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor.
An inhibitor of thrombin has the potential to interfere with essentially all clot-based …

Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …